Related Experiment Videos
Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment
Richard J Klasa1, Amanda M Gillum, Robert E Klem
1Department of Advanced Therapeutics, British Columbia Cancer Agency, Vancouver, Canada.
Antisense & Nucleic Acid Drug Development
|August 7, 2002
Summary
Oblimersen sodium, an antisense oligonucleotide, effectively reduces Bcl-2 protein, enhancing cancer therapy. Clinical trials are evaluating its synergistic effects with various treatments across multiple cancer types.
Area of Science:
- Oncology
- Molecular Biology
- Anticancer Therapeutics
Background:
- Bcl-2 protein inhibits apoptosis, leading to chemoresistance.
- Anticancer therapies target apoptotic pathways.
- Oblimersen sodium is an antisense oligonucleotide targeting Bcl-2.
Purpose of the Study:
- To evaluate Oblimersen sodium's efficacy as an anticancer therapeutic.
- To demonstrate the antisense effect of Oblimersen sodium in human tumors.
- To assess the synergistic potential of Oblimersen sodium with other anticancer agents.
Main Methods:
- Oblimersen sodium designed to bind bcl-2 mRNA, causing degradation.
- Demonstration of Bcl-2 protein downregulation in human tumors.
- Preclinical and clinical studies in various hematologic malignancies and solid tumors.
Main Results:
- Oblimersen sodium is the first oligonucleotide to show an antisense effect in human tumors.
- Documented downregulation of Bcl-2 protein.
- Evidence suggests Oblimersen sodium synergizes with cytotoxic and biologic agents.
Conclusions:
- Oblimersen sodium represents a promising apoptosis-modulating strategy.
- Ongoing clinical trials are evaluating Oblimersen sodium in combination therapies.
- Potential for enhancing efficacy of anticancer treatments across diverse cancers.